Welcome to NDF Research
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog
Historically important PCT patent applications made by the Life Sciences sector in Australia and New Zealand
Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (21 August 2018)

Here are what we consider to have been the most notable PCT patent applications relevant to the Life Sciences sector in Australia and New Zealand up to 27 August 1998:

Australia

  • WO/1998/036054, Novel molecules, Amrad, 20 August 1998
  • WO/1998/033917, Vascular Endothelial Growth Factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof, Ludwig Institute for Cancer Research and University of Helsinki, 6 August 1998
  • WO/1998/032769, Antigen, Auspharm International Ltd, 30 July 1998
  • WO/1998/031819, Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase, Montech Medical Developments Pty Ltd and Rondole Pty Ltd, 23 July 1998
  • WO/1998/031739, A process for preparing polymeric microgels, University of Melbourne, 23 July 1998
  • WO/1998/030124, Insect repellent substrate for headwear, Lice Busters International Pty Ltd, 16 July 1998
  • WO/1998/027996, A method of treatment and prophylaxis, Amrad, 2 July 1998
  • WO/1998/027927, Apparatus and method for coating a material, Scientec Research Pty Ltd, 2 July 1998
  • WO/1998/027805, Antimicrobial proteins, Cooperative Research Centre for Tropical Plant Pathology, 2 July 1998
  • WO/1998/026784, A method for preventing or controlling cataract, University of Sydney, 25 June 1998
  • WO/1998/023639, ShK toxin compositions and methods of use, University of Florida, University of California, Bachem Bioscience and Biomolecular Research Institute, 4 June 1998
  • WO/1998/023291, Percutaneous delivery system, Soltec Research Pty Ltd, 4 June 1998
  • WO/1998/020023, Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines, Walter and Eliza Hall Institute of Medical Research, 14 May 1998
  • WO/1998/018918, Stable expression of triple helical proteins, Commonwealth Scientific and Industrial Research Organisation, 7 May 1998
  • WO/1998/017320, Use of hyaluronan in gene therapy, Hyal Pharmaceutical Corporation, 30 April 1998
  • WO/1998/015267, Method for the treatment of neurological or neuropsychiatric disorders, Clarencew Pty Ltd, 16 April 1998
  • WO/1998/013379, Method of cell inhibition using polypeptides derived from the venom of the Australian jumper ant Myrmecia pilosula, Northern Sydney Area Health Service, 2 April 1998
  • WO/1998/008533, Sustained peptide-release formulation, Peptech, 5 March 1998
  • WO/1998/008503, Therapeutic methods and compositions involving isoflavones, Novogen, 5 March 1998
  • WO/1998/007832, Recombinant Vascular Endothelial cell Growth Factor D (VEGF-D), Ludwig Institute for Cancer Research and University of Helsinki, 26 February 1998
  • WO/1998/005768, Improved nucleic acids encoding a chimeric glycosyltransferase, Austin Research Institute, 12 February 1998
  • WO/1998/003573, Angiogenic inhibitory compounds, Biomolecular Research Institute, 29 January 1998
  • WO/1998/001465, Neuroactive peptide, Howard Florey Institute of Experimental Physiology and Medicine, 15 January 1998
  • WO/1997/047644, T cell antigen receptor peptides, Northern Sydney Area Health Services, 18 December 1997
  • WO/1997/045449, Dendritic cell receptor, Derek Hart, 4 December 1997
  • WO/1997/045444, EBV CTL epitopes, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Biotech Australia Pty Ltd and CSL Ltd, 4 December 1997
  • WO/1997/043005, Targeted hysteresis hyperthermia as a method for treating diseased tissue, Paragon Medical, Bruce Gray and Stephen Jones, 20 November 1997
  • WO/1997/042958, Treatment of asthma and airway diseases, Amrad, 20 November 1997
  • WO/1997/041886, Stimulation of host defence mechanisms against tumors, Pharma Pacific Pty Ltd, 13 November 1997
  • WO/1997/041884, Method of treatment, Pharma Pacific Pty Ltd, 13 November 1997
  • WO/1997/041839, Taste masked liquid suspensions, F.H. Faulding & Co., 13 November 1997
  • WO/1997/038688, Methods of treating immunopathologies using polyunsaturated fatty acids, Peptech and Women's and Children's Hospital Adelaide, 23 October 1997
  • WO/1997/038681, A method for detection of potential co-antioxidants, Heart Research Institute, 23 October 1997
  • WO/1997/037013, Asymmetric hammerhead ribozymes, Commonwealth Scientific and Industrial Research Organisation, 9 October 1997
  • WO/1997/036923, Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis, University of Melbourne and Victorian Dairy Industry Authority, 9 October 1997
  • WO/1997/035971, A novel mammalian gene, BCL-W, belongs to the Bcl-2 family of apoptosis-controlling genes, Amrad, 2 October 1997
  • WO/1997/034639, Animal model for transplantation, Fremantle Hospital, 25 September 1997
  • WO/1997/034615, Enhancement of microbial colonisation of the gastrointestinal tract, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 25 September 1997
  • WO/1997/034592, Selection and/or enhancement of resident microorganisms in the gastrointestinal tract, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 25 September 1997
  • WO/1997/034591, Alteration of microbial populations in the gastrointestinal tract, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 25 September 1997
  • WO/1997/033614, Use of Coxiella bacteria to treat autoimmune disease, Australian National University, 18 September 1997
  • WO/1997/032979, Inhibition of proliferation of cells, University of New South Wales, 12 September 1997
  • WO/1997/029767, Stabilised growth hormone formulation and method of preparation thereof, CSL Ltd and Monash University, 21 August 1997
  • WO/1997/029735, Dermal penetration enhancers and drug delivery systems involving same, Monash University, 21 August 1997
  • WO/1997/028190, Cytokine antagonists and agonists, Medvet Science Pty Ltd, 7 August 1997
  • WO/1997/028185, Anti-microbial protein, Cooperative Research Centre for Plant Pathology, 7 August 1997
  • WO/1997/026886, Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria, Pharmacy and Therapeutic Advisory Consultancy Pty Ltd, 31 July 1997
  • WO/1997/025339, Composition and method for delivery of nucleic acids, Commonwealth Scientific and Industrial Research Organisation, 17 July 1997
  • WO/1997/024373, Monoclonal antibody antagonists to haemopoietic growth factors, Medvet Science Pty Ltd, 10 July 1997
  • WO/1997/022701, Equine rhinovirus 1 proteins, University of Melbourne, 26 June 1997
  • WO/1997/022345, Phospholipid and propylene glycol based lubricant, Macnaught Medical Pty Ltd, 26 June 1997
  • WO/1997/021727, Mycoplasma recombinant polypeptide vaccines, University of Melbourne, 19 June 1997
  • WO/1997/020050, Therapeutic and diagnostic compositions, Daratech Pty Ltd and Pig Research and Development Corporation, 5 June 1997
  • WO/1997/019177, Synthetic mammalian α-n-acetylglucosaminidase and genetic sequences encoding same, Women's and Children's Hospital, 29 May 1997
  • WO/1997/017406, UV absorbing compositions, M & J Bos Consultants Pty Ltd, 15 May 1997
  • WO/1997/016977, Liquid colostrum for dairy products, Northfield Laboratories Pty Ltd, 15 May 1997
  • WO/1997/016542, Diagnostics and treatments of periodontal disease, University of Melbourne, Victorian Dairy Industry Authority, 9 May 1997
  • WO/1997/016532, Immunity against Actinobacillus pleuropneumoniae's RTX-toxin APX, Commonwealth Scientific and Industrial Research Organisation and Pig Research and Development Corporation, 9 May 1997
  • WO/1997/016531, Immunity against Pasteurella haemolytica leukotoxin, Commonwealth Scientific and Industrial Research Organisation and Pig Research and Development Corporation, 9 May 1997
  • WO/1997/016064, Methods and compositions for the reduction of xenotransplantation rejection, Mount Sinai Medical Center and Austin Research Institute, 9 May 1997
  • WO/1997/015663, A novel haemopoietin receptor and genetic sequences encoding same, Amrad, 1 May 1997
  • WO/1997/014438, Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and a kappa-2 opioid agonist, University of Queensland and The Lynx Project Ltd, 24 April 1997
  • WO/1997/014415, Analgesic immediate and controlled release pharmaceutical composition, F.H. Faulding & Co., 24 April 1997
  • WO/1997/013744, 3-amino-propoxyphenyl derivatives (i), University of Melbourne, 17 April 1997
  • WO/1997/012972, Regulated genes and uses thereof, Salvatore Oliviero and University of Siena, 10 April 1997
  • WO/1997/011963, Anti-galα(1,3)gal antibody binding peptides, Austin Research Institute, 3 April 1997
  • WO/1997/006826, Gene therapy using ovine adenoviral vectors, Commonwealth Scientific and Industrial Research Organisation, 27 February 1997
  • WO/1997/005250, Receptor ligand VEGF-C, Kari Alitalo, Vladimir Joukov, and University of Helsinki, 13 February 1997
  • WO/1997/005164, Papillomavirus polyprotein constructs, CSL Ltd and University of Queensland, 13 February 1997
  • WO/1997/004776, Radioprotectors, Inner and Eastern Health Care Network, 13 February 1997
  • WO/1997/002831, Herbal compositions for hepatic disorders, Cathay Herbal Laboratories Pty Ltd, 30 January 1997
  • WO/1997/000695, Haemopoietic growth factor antagonists and uses therefor, Bresagen and Medvet Science Pty Ltd, 9 January 1997
  • WO/1997/000693, Novel formulation for peptide release, Peptech, 9 January 1997
  • WO/1997/000086, Immunogenic preparation and method for improving the productivity of ruminant animals, Commonwealth Scientific and Industrial Research Organisation, 3 January 1997
  • WO/1997/000052, Denture retaining composition, Confi-Dent Pty Ltd, 3 January 1997
  • WO/1996/040906, Optimized minizymes and miniribozymes and uses thereof, Commonwealth Scientific and Industrial Research Organisation, 19 December 1996
  • WO/1996/039499, TNF-α ribozymes, TNF-α ribozyme binding protein and degradation resistant mRNA derivatives linked to TNF-α ribozymes, Gene Shears Pty Ltd, 12 December 1996
  • WO/1996/038186, Chemotherapeutic compositions, Chemeq, 5 December 1996
  • WO/1996/034614, Method of preventing or treating alimentary tract damage due to chemotherapy or radiation, Gropep, 7 November 1996
  • WO/1996/033726, Preparation and use of sulfated oligosaccharides, Australian National University, 31 October 1996
  • WO/1996/033220, Protective Helicobacter antigens, CSL Ltd and University of New South Wales, 24 October 1996
  • WO/1996/029392, Methods for microbial regulation, University of New South Wales, 26 September 1996
  • WO/1996/028476, Process for glucan preparation and therapeutic uses of glucan, Novogen, 19 September 1996
  • WO/1996/028472, Antigen composition against Mycoplasma, University of Melbourne, 19 September 1996
  • WO/1996/028177, Method and vaccine for prevention of over-production of acid in the rumen or gut of animals, University of New England, 19 September 1996
  • WO/1996/027666, Novel avian cytokines and genetic sequences encoding same, Commonwealth Scientific and Industrial Research Organisation, 12 September 1996
  • WO/1996/027376, Corticosteroid-containing pharmaceutical composition, Medeva plc, 12 September 1996
  • WO/1996/026218, Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM), Amrad, 29 August 1996
  • WO/1996/022306, Novel peptide, Northern Sydney Area Health Service, 25 July 1996
  • WO/1996/022303, Therapeutic compound - fatty acid conjugates, Commonwealth Scientific and Industrial Research Organisation, 25 July 1996
  • WO/1996/020703, Compounds for veterinary and medicinal applications, Australian Biomedical Company Pty Ltd, 11 July 1996
  • WO/1996/019496, Variants of Human Papilloma Virus antigens, CSL Ltd and University of Queensland, 27 June 1996
  • WO/1996/019471, Polymerisable monomers and polymers, Commonwealth Scientific and Industrial Research Organisation, 27 June 1996
  • WO/1996/017855, Anti-tumour agents, Griffith University, 13 June 1996
  • WO/1996/017057, SOX-9 gene and protein and use in the regeneration of bone or cartilage, University of Queensland, 6 June 1996
  • WO/1996/016950, HIV protease inhibitors, University of Queensland, 6 June 1996
  • WO/1996/014062, A delivery system for antimethanogenic agents, Commonwealth Scientific and Industrial Research Organisation, 17 May 1996
  • WO/1996/013507, Synthetic polyunsaturated fatty acid analogues, Peptech and Women's and Children's Hospital Adelaide, 9 May 1996
  • WO/1996/012466, Controlled release container with core and outer shell, Daratech Pty Ltd, 2 May 1996
  • WO/1996/011944, Synthetic peptides and vaccines comprising same, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Biotech Australia Pty Ltd and CSL Ltd, 25 April 1996
  • WO/1996/011015, Hydration compositions for human or animal bodies, Aqua Connexions Pty Ltd, 18 April 1996
  • WO/1996/008512, Polypeptides with Fc binding ability, Austin Research Institute, 21 March 1996
  • WO/1996/008261, Probiotic compositions, University of New South Wales, Burns Philp, Commonwealth Scientific and Industrial Research Organisation, Arnott's Biscuits, Gist-Brocades and Goodman Fielder, 21 March 1996
  • WO/1996/006937, Improvements in production of proteins in host cells, Austin Research Institute, 7 March 1996
  • WO/1996/006629, High-affinity response-selective C-terminal analogs of c5a anaphylatoxin, University of Nebraska and University of Queensland, 7 March 1996
  • WO/1996/006185, Assay for the detection of proteases, Commonwealth Scientific and Industrial Research Organisation, 29 February 1996
  • WO/1996/005218, Delivery of nucleic acids, Commonwealth Scientific and Industrial Research Organisation, 22 February 1996
  • WO/1996/001636, A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders, Royal Children's Hospital, 25 January 1996
  • WO/1995/035131, Controlled release device and method, Unasco Pty Ltd, 28 December 1995
  • WO/1995/034595, Antiviral dendrimers, Biomolecular Research Institute, 21 December 1995
  • WO/1995/033482, Treatment and prevention of Helicobacter infection, CSL Ltd and University of New South Wales, 14 December 1995
  • WO/1995/031476, Recombinant Papilloma Virus L1, University of Queensland, 23 November 1995
  • WO/1995/030436, An adjuvant, Commonwealth Scientific and Industrial Research Organisation, 16 November 1995
  • WO/1995/029933, Modified milk growth factor, Gropep, 9 November 1995
  • WO/1995/027483, Carotenoid agent for inhibiting the conversion of epithelial cells to tumours, Lance Schlipalius, Julie Buckmeier and Frank Meyskens Jr, 19 October 1995
  • WO/1995/024925, Cytotoxic T-cell epitopes, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Biotech Australia Pty Ltd and CSL Ltd, 21 September 1995
  • WO/1995/022993, Method and device for the provocation of air passage narrowing and/or the induction of sputum, Central Sydney Area Health Service, 31 August 1995
  • WO/1995/022969, Method of treatment of cancer as well as method of inhibition of lactation in mammals, University of Queensland and Australian National University, 31 August 1995
  • WO/1995/022563, Antigenic preparation for treatment or prevention of Helicobacter infection, CSL Ltd and University of New South Wales, 24 August 1995
  • WO/1995/021912, Non-pathogenic strains of HIV-1, Macfarlane Burnet Centre for Medical Research and Australian Red Cross Society, 17 August 1995
  • WO/1995/021192, Malaria merozoite antigen subunit vaccine, Saramane Pty Ltd, 10 August 1995
  • WO/1995/020659, Modified Papilloma Virus L2 protein and VLPs formed therefrom, University of Queensland and CSL Ltd, 3 August 1995
  • WO/1995/019841, Particulate material, Bruce Gray, 27 July 1995
  • WO/1995/018854, Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs, Gene Shears Pty Ltd, 13 July 1995
  • WO/1995/018145, Conjugates of human mucin and a carbohydrate polymer and their use in cancer treatment, Ilexus Pty Ltd, 6 July 1995
  • WO/1995/017208, Prophylaxis of allergic disease, TVW Telethon Institute for Child Health Research, 29 June 1995
  • WO/1995/015377, Plant arabinogalactan protein (AGP) genes, Albright & Wilson, 8 June 1995
  • WO/1995/015339, Antagonists to chaperonin 10, University of Queensland, 8 June 1995
  • WO/1995/015338, Chaperonin 10, University of Queensland, 8 June 1995
  • WO/1995/013818, A method for treating cardiac dysfunction and pharmaceutical compositions useful therefor, Baker Medical Research Institute, 26 May 1995
  • WO/1995/013801, Fatty acid delivery system, Commonwealth Scientific and Industrial Research Organisation, 26 May 1995
  • WO/1995/013798, Controlled release preparation, Cancer Research Institute, 26 May 1995
  • WO/1995/013096, Labelled diagnostic compositions and methods of their use, Peptide Delivery Systems Pty Ltd, 18 May 1995
  • WO/1995/011253, A method for enhancing neurone survival and agents useful for same, Walter and Eliza Hall Institute of Medical Research, 27 April 1995
  • WO/1995/011041, Method for improving utilisation of nutrients by ruminant or ruminant-like animals, Commonwealth Scientific and Industrial Research Organisation, 27 April 1995
  • WO/1995/009622, Polyunsaturated fatty acids and uses thereof, Peptech and Women's and Children's Hospital Adelaide, 13 April 1995
  • WO/1995/008632, Immunoreactive antigens of Hepatitis E Virus, Macfarlane Burnet Centre for Medical Research, 30 March 1995
  • WO/1995/008562, Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition, Anadis, 30 March 1995
  • WO/1995/008339, Treatment or prevention of Crohn's disease and/or ulcerative colitis, Peptech, 30 March 1995
  • WO/1995/008338, Method for the treatment or prevention of eczema/dermatitis, Peptech, 30 March 1995
  • WO/1995/004529, Composition for treatment of hangovers, Musashi Pty Ltd, 16 February 1995
  • WO/1995/004075, Haemopoietic growth factor antagonists, Medvet Science Pty Ltd, 9 February 1995
  • WO/1995/003824, Treatment of H. pylori associated gastroduodenal disease, CSL Ltd and University of New South Wales, 9 February 1995
  • WO/1995/003807, Treatment of Age-related Macular Degeneration, University of Sydney, 9 February 1995
  • WO/1994/029461, Method for specific silencing of genes by DNA methylation, Commonwealth Scientific and Industrial Research Organisation, 22 December 1994
  • WO/1994/028886, Use of natural products and related synthetic compounds for the treatment of cardiovascular disease, University of Sydney, 22 December 1994
  • WO/1994/028015, LHRH antagonists, Biotech Australia Pty Ltd, 8 December 1994
  • WO/1994/027613, Vitamin B12 mediated oral delivery systems for GCSF and EPO, Biotech Australia Pty Ltd, 8 December 1994
  • WO/1994/027598, Antiparasitic compositions, Commonwealth Scientific and Industrial Research Organisation, 8 December 1994
  • WO/1994/026776, Therapeutic compounds, Biomolecular Research Institute, Macfarlane Burnet Centre for Medical Research and Commonwealth Scientific and Industrial Research Organisation, 24 November 1994
  • WO/1994/023748, Administration of vaso-active agent and therapeutic agent, University of Queensland, 27 October 1994
  • WO/1994/021232, Water dispersible therapeutic compounds, Betatene, 29 September 1994
  • WO/1994/021231, Therapeutic agent for the treatment of melanomas, Betatene, 29 September 1994
  • WO/1994/018984, Ecdysones used to improve productivity of ruminants, Commonwealth Scientific and Industrial Research Organisation, 1 September 1994
  • WO/1994/018328, Protein Kinase C (iota), Garvan Institute of Medical Research, 18 August 1994
  • WO/1994/015636, Vaccine preparations, CSL Ltd, 21 July 1994
  • WO/1994/014958, Synthetic polynucleotides, University of Sydney, 7 July 1994
  • WO/1994/013688, DNA-armed ribozymes and minizymes, Gene Shears Pty Ltd, 23 June 1994
  • WO/1994/010331, Angiogenesis inhibitory antibodies, Australian National University, 11 May 1994
  • WO/1994/010314, Allergenic proteins and peptides from Johnson grass pollen, University of Melbourne, 11 May 1994
  • WO/1994/010301, TNF-α ribozymes and degradation resistant mRNA derivatives linked to TNF-α ribozymes, Gene Shears Pty Ltd, 11 May 1994
  • WO/1994/009149, Monoclonal antibody, Amrad, 28 April 1994
  • WO/1994/007921, Target binding polypeptide, Commonwealth Scientific and Industrial Research Organisation, 14 April 1994
  • WO/1994/005790, Cloning and sequencing of allergens of Dermatophagoides (house dust mite), Immulogic Pharmaceutical Corporation, 17 March 1994
  • WO/1994/005311, Retro-, inverso-, and retro-inverso synthetic peptide analogues, Deakin Research Ltd, 17 March 1994
  • WO/1994/003633, Assessment of trans-acting factors allelic variation, Garvan Institute of Medical Research, 17 February 1994
  • WO/1994/003160, Pelletised pharmaceutical composition, F.H. Faulding & Co., 17 February 1994
  • WO/1994/001464, Leukaemia Inhibitory Factor-binding protein, Amrad, 20 January 1994
  • WO/1994/000146, Treatment for sensitive teeth, University of Melbourne and Victorian Dairy Industry Authority, 6 January 1994
  • WO/1993/024650, Therapeutic compositions, Monash University, 9 December 1993
  • WO/1993/024528, Equine herpesvirus glycoproteins, University of Melbourne, 9 December 1993
  • WO/1993/024454, High cis beta-carotene composition, Betatene, 9 December 1993
  • WO/1993/023069, Health supplements containing phyto-oestrogens, analogues or metabolites thereof, Graham Kelly, 25 November 1993
  • WO/1993/020102, Peptide T and related peptides in the treatment of inflammation, including Multiple Sclerosis, Peptech and Drug Royalty Corporation, 14 October 1993
  • WO/1993/017108, Analogous peptides of the internal image of a viral protein, Centre National de la Recherche Scientifique and Monash University, 2 September 1993
  • WO/1993/016179, Mammalian Sos - a regulator/effector of tyrosine kinase signalling, Howard Florey Institute of Experimental Physiology and Medicine, 19 August 1993
  • WO/1993/012806, A method for the treatment of tumours and sarcomas, Amrad, 8 July 1993
  • WO/1993/010244, Synthetic alpha-l-iduronidase and genetic sequences encoding same, Women's and Children's Hospital, 27 May 1993
  • WO/1993/009227, Human neuropeptide y-y1 receptor, Garvan Institute of Medical Research, 13 May 1993
  • WO/1993/007833, Biocompatible implant for the timing of ovulation in mares, Peptech, 29 April 1993
  • WO/1993/007171, Human Il-3 variants, Medvet Science Pty Ltd, 15 April 1993
  • WO/1993/006856, Treating ophthalmic fibrosis using interferon-alpha, Mark Gillies, Nigel Morlet and Marc Sarossy, 15 April 1993
  • WO/1993/004690, Method for the treatment of the complications and pathology of diabetes, Peptech and King's College London, 18 March 1993
  • WO/1993/004174, Ryegrass pollen allergen, University of Melbourne, 4 March 1993
  • WO/1993/002706, Self-adjuvanting peptide vaccine delivery system and production thereof, Commonwealth Scientific and Industrial Research Organisation, 18 February 1993
  • WO/1993/002184, Papilloma virus vaccine, University of Queensland and CSL Ltd, 4 February 1993
  • WO/1993/001215, Pla2 inhibitory compounds, Garvan Institute of Medical Research, 21 January 1993
  • WO/1993/001211, Peptide which abrogates TNF and/or LPS toxicity, Peptech, 21 January 1993
  • WO/1993/000425, A novel receptor-type tyrosine kinase and use thereof, Amrad, 7 January 1993
  • WO/1993/000084, Methods and compositions for treating malaria and other diseases, Adelaide Children's Hospital, 7 January 1993
  • WO/1992/018526, Production of phosphopeptides from casein, University of Melbourne and Victorian Dairy Industry Authority, 29 October 1992
  • WO/1992/017167, Oral delivery systems for microparticles, Biotech Australia Pty Ltd, 15 October 1992
  • WO/1992/017165, A single dose vaccination system, CSL Ltd and Monash University, 15 October 1992
  • WO/1992/015681, Human galanin, cDNA clones encoding human galanin and a method of producing human galanin, Garvan Institute of Medical Research, 17 September 1992
  • WO/1992/014485, A method for the diagnosis and treatment of Glutamic Acid Decarboxylase autoantigen associated diseases, Amrad, 3 September 1992
  • WO/1992/013890, Nematode vaccine, Biotech Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 20 August 1992
  • WO/1992/013889, Nematode vaccine, Biotech Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 20 August 1992
  • WO/1992/010511, Compounds and compositions which inhibit bone resorption, University of Melbourne and Genentech, 25 June 1992
  • WO/1992/007582, Corynebacteria and related organisms as vaccine vectors, Commonwealth Scientific and Industrial Research Organisation, 14 May 1992
  • WO/1992/005192, T-cell epitopes, Biotech Australia Pty Ltd, 2 April 1992
  • WO/1992/004376, Novel chemotactic factor, Heart Research Institute, 19 March 1992
  • WO/1992/003458, Non-A, Non-B Hepatitis Virus antigen, diagnostic methods and vaccines, New York Blood Center and Pharmacia, 5 March 1992
  • WO/1992/002624, Cloning and expression of toxoplasma antigens and use of recombinant antigens, Flinders University, 20 February 1992
  • WO/1992/002623, Cloning and expression of a rhoptry associated protein of P. falciparum, Saramane Pty Ltd, 20 February 1992
  • WO/1992/000994, Growth-promoting agent, Gropep, 23 January 1992
  • WO/1991/019789, Endonucleases, Commonwealth Scientific and Industrial Research Organisation, 26 December 1991
  • WO/1991/018097, CD46 variants, University of Melbourne, 28 November 1991
  • WO/1991/016073, Oral vaccine comprising antigen surface-associated with red blood cells, University of Newcastle, 31 October 1991
  • WO/1991/014443, A method for regulating neuron development and maintenance, Amrad, 3 October 1991
  • WO/1991/013908, Neutrophil stimulating peptides, Peptech, 19 September 1991
  • WO/1991/012018, Method for treating intestinal diseases, Gropep, 22 August 1991
  • WO/1991/008752, Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor, Amrad, 27 June 1991
  • WO/1991/007186, Anti-inflammatory compositions and methods, University of Melbourne, 30 May 1991
  • WO/1991/002078, Tumour Necrosis Factor binding ligands, Peptech, 21 February 1991
  • WO/1991/002063, Improvements in Granulocyte-Macrophage Colony-Stimulating Factor receptor and derivatives thereof, Amrad, 21 February 1991
  • WO/1990/015140, Production of IBDV vp2 in highly immunogenic form, Commonwealth Scientific and Industrial Research Organisation, 13 December 1990
  • WO/1990/014433, Monoclonal antibodies which recognise malignant cells from bladder carcinomas, University of Sydney and Central Sydney Area Health Service, 29 November 1990
  • WO/1990/012321, Halogenated DNA ligand radiosensitisers for cancer therapy, Cancer Institute, University of Melbourne and Anti-Cancer Council of Victoria, 18 October 1990
  • WO/1990/009995, UV-absorbing compounds and compositions, ICI Australia and Australian Institute of Marine Science, 7 September 1990
  • WO/1990/008188, Leukaemia Inhibitory Factor from livestock species and use thereof to enhance implantation and development of embryonic cells, Amrad, 26 August 1990
  • WO/1990/003433, Vaccine, Biotechnology Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 5 April 1990
  • WO/1990/001335, Treatment of gastro-intestinal disorders, Thomas Borody, 22 February 1990
  • WO/1990/001319, Use of castanospermine as an anti-inflammatory and immunosuppressant agent, Australian National University, 22 February 1990
  • WO/1990/000569, Acid-Labile Subunit (ALS) of Insulin-like Growth Factor (IGF) binding protein complex, Central Sydney Area Health Service, 25 January 1990
  • WO/1989/005852, Ribozymes, Macphillamy Cummins & Gibson, 29 June 1989
  • WO/1989/001514, Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine, University of Melbourne and University of Sydney, 23 February 1989
  • WO/1989/000163, Vaccines against animal parasitic nematodes, Biotechnology Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 12 January 1989
  • WO/1988/009376, Method and compositions for making ACSF and ACSF antagonists, Genentech and University of Melbourne, 1 December 1988
  • WO/1988/007602, Process for dyeing wool and other keratin fibres, Commonwealth Scientific and Industrial Research Organisation, 6 October 1988
  • WO/1988/007548, Leukaemia Inhibitory Factor, Amrad, 6 October 1988
  • WO/1988/007060, Anti-inflammatory compounds and compositions, Arthropharm Pty Ltd, 22 September 1988
  • WO/1988/006627, Plant gum material and use thereof in food products, Bio Polymers Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 7 September 1988
  • WO/1988/005301, Sulphated polysaccharides having anti-metastatatic and/or anti-inflammatory activity, Australian National University, 28 July 1988
  • WO/1988/004689, Primary biliary cirrhosis autoantigen, Amrad, 30 June 1988
  • WO/1988/003929, Vaccine containing tick antigens, Biotechnology Australia Pty Ltd and Commonwealth Scientific and Industrial Research Organisation, 2 June 1988
  • WO/1988/000971, Recombinant vaccine, Commonwealth Scientific and Industrial Research Organisation and Australian National University, 11 February 1988
  • WO/1988/000596, A protein active in humoral hypercalcemia of malignancy PTHrP, University of Melbourne, 28 January 1988
  • WO/1987/006590, Immunopotentiation, Bioenterprises Pty Ltd, 5 November 1987
  • WO/1987/002251, Oral delivery of biologically active substances bound to vitamin B12, or analogues thereof, Biotechnology Australia Pty Ltd, 23 April 1987
  • WO/1986/007060, Cloning and expression of host-protective immunogens of IBDV, Commonwealth Scientific and Industrial Research Organisation, 4 December 1986
  • WO/1986/006635, Oral vaccines, Biotechnology Australia Pty Ltd, 20 November 1986
  • WO/1986/006076, Recombinant inhibin, Biotechnology Australia Pty Ltd, Monash University, Prince Henry's Hospital and St. Vincent's Institute of Medical Research, 23 October 1986
  • WO/1985/005122, Rotavirus, University of Melbourne, 21 November 1985

New Zealand

  • WO/1998/035567, Gelling agents and gels containing them, University of Otago and Kiwitech Ltd, 20 August 1998
  • WO/1998/031799, Polynucleotides and polypeptides encoding receptors, Human Genome Sciences, 23 July 1998
  • WO/1998/025470, A method of biological control, Kelvin Duncan and Angus Macrae , 18 June 1998
  • WO/1998/015658, Compositions and methods for treating viral infections, Probe International, 16 April 1998
  • WO/1998/014202, Regulation of neural enzymes, University of Auckland, 9 April 1998
  • WO/1998/013056, Beta-glucan products and extraction processes from cereals, Gracelinc Ltd, 2 April 1998
  • WO/1998/008542, Compounds and methods for treatment and diagnosis of mycobacterial infections, Genesis Research & Development and Vialactia Bioscience, 5 March 1998
  • WO/1997/046204, Injectable compositions, Ashmont Holdings Ltd and Colin Harvey, 11 December 1997
  • WO/1997/040776, Synchronising of animal oestrus and intra vaginal devices useful therein, Michael Rathbone, Craig Bunt and Shane Burggraaf, 6 November 1997
  • WO/1997/038704, Treatment of bone disorders with adrenomedullin, University of Auckland and Tulane University, 23 October 1997
  • WO/1997/011709, Anthelmintic macrocyclic lactone compositions, Ashmont Holdings Ltd, 3 April 1997
  • WO/1997/007101, Radiation-activated cytotoxin therapy, University of Auckland, 27 February 1997
  • WO/1996/027377, Methods and compositions for sedating, anaesthetising and euthanising aquatic organisms, New Zealand Institute for Crop and Food Research, 12 September 1996
  • WO/1996/019235, Enhancement of fetal growth by administration of insulin-like growth factor-1 (IGF-1), University of Auckland, 27 June 1996
  • WO/1996/002269, Therapeutic method and compounds of use therein, University of Auckland, 1 February 1996
  • WO/1995/024216, Prevention of diabetes, University of Auckland, 14 September 1995
  • WO/1995/023590, Anthelmintic preparation, Bomac Laboratories, 8 September 1995
  • WO/1995/019763, Device for administration of beneficial materials to ruminants, New Zealand Pastorial Agriculture Research Institute, 27 July 1995
  • WO/1995/017511, Mycobacteria virulence factors and a method for their identification, Agresearch New Zealand Pastoral Agriculture Research Institute and Yeshiva University, 29 June 1995
  • WO/1995/017204, Composition and methods to improve neural outcome, University of Auckland, 29 June 1995
  • WO/1995/012409, Dendritic cell-specific antibodies and methods for their preparation, Derek Hart, 11 May 1995
  • WO/1994/027954, Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents, University of Auckland, 8 December 1994
  • WO/1993/017030, Immunological detection of organophosphates, Horticulture and Food Research Institute of New Zealand, 2 September 1993
  • WO/1993/008284, M. paratuberculosis promoter and use thereof in immunogenic sequence expression, Institut Pasteur and Massey University, 29 April 1993
  • WO/1993/002695, IGF-1 to improve the neural condition, Genentech and University of Auckland, 18 February 1993
  • WO/1998/035567, Gelling agents and gels containing them, University of Otago and Kiwitech Ltd, 20 August 1998
  • WO/1998/031799, Polynucleotides and polypeptides encoding receptors, Human Genome Sciences, 23 July 1998
  • WO/1998/025470, A method of biological control, Kelvin Duncan and Angus Macrae , 18 June 1998

Copyright © 2018 NDF Research
Proudly powered by Weebly
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog